Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer / 中华肿瘤杂志
Chinese Journal of Oncology
; (12): 297-307, 2022.
Article
de Zh
| WPRIM
| ID: wpr-935214
Bibliothèque responsable:
WPRO
ABSTRACT
The mutation rate of anaplastic lymphoma kinase (ALK) in patients with non-small cell lung cancer is 3% to 7%. Due to its low mutation rate and better long-term survival compared with epidermal growth factor receptor-positive non-small cell lung cancer patients, therefore, it's called "diamond mutation". At present, there are three generations of ALK tyrosine kinase inhibitor (TKI) drugs in the world. The first-generation ALK-TKI drug approved in China is crizotinib, and the second-generation drugs are alectinib, ceritinib and ensartinib. Among them, ensartinib is an ALK-TKI domestically developed, and its efficacy is similar to that of alectinib. The main adverse event is transient rash, and compliance to ensartinib is better from the perspective of long-term survival of patients. The manifestation of rash caused by ensartinib is different from that of other ALK-TKI drugs. In order to facilitate clinical application and provide patients with more treatment options, under the guidance of the Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association, this article collects and summarizes the common adverse reactions of ensartinib. Based on the clinical practice, a clear adverse classification and specific treatment plan are formulated, in order to provide a corresponding reference for clinicians to make more comprehensive clinical decisions.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pipérazines
/
Pyridazines
/
Carbazoles
/
Carcinome pulmonaire non à petites cellules
/
Consensus
/
Inhibiteurs de protéines kinases
/
Exanthème
/
Kinase du lymphome anaplasique
/
Tumeurs du poumon
Type d'étude:
Guideline
/
Prognostic_studies
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Oncology
Année:
2022
Type:
Article